CASOKEFAMIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C33H40N6O7
Molecular Weight	632.7067
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H](NC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](C)C(=O)N[C@@H](CC3=CC=C(O)C=C3)C(N)=O

InChI

InChIKey=XDRHVZLDLNGKLM-FLVVDCEDSA-N

InChI=1S/C33H40N6O7/c1-19(36-32(45)26(34)16-22-8-12-24(40)13-9-22)31(44)39-28(18-21-6-4-3-5-7-21)33(46)37-20(2)30(43)38-27(29(35)42)17-23-10-14-25(41)15-11-23/h3-15,19-20,26-28,40-41H,16-18,34H2,1-2H3,(H2,35,42)(H,36,45)(H,37,46)(H,38,43)(H,39,44)/t19-,20-,26+,27+,28+/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11021978 | https://www.ncbi.nlm.nih.gov/pubmed/10793229 | https://www.ncbi.nlm.nih.gov/pubmed/8466524

Casokefamide is a synthetic peptide derived from the beta-casomorphin sequence, designed to increase the resistance to gastric proteases. . Casokefamide binds to both mu and delta-opioid receptors, while beta-casomorphins and its fragments are typical mu-opioid receptor agonists. Furthermore, casokefamide can affect gastric acid and pancreatic exocrine secretions and also gastrointestinal motility.

Originator

Approval Year

PubMed

Title	Date	PubMed
Effects of oral casokefamide on plasma levels, tolerance, and intestinal transit in man.	2000 Mar	10793229

Patents

Sample Use Guides

In Vivo Use Guide

16.0 mg/day

Route of Administration: Oral

Name

Type

Language

CASOKEFAMIDE

Official Name

English

casokefamide [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C67413